Close Menu

cervical pre-cancer

The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.

Profiling microbial communities in cervicovaginal samples from women carrying high-risk HPV strains, researchers found possible markers of pre-cancer progression.

The new test uses the number of sequencing reads at specific early and late HPV transcripts as a biomarker for high-grade cytology.

The test will guide clinical decision making related to Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus.

A pair of new studies evaluated the effectiveness of cytologic and HPV-based testing approaches at varied screening intervals for identifying women at risk of cervical cancer.

Researchers profiled cervical microbe communities in relation to HPV, HIV, and cervical cytology status, identifying microbial shifts in high-grade lesions and HIV-positive cases.

Simulated population data suggests that the lifetime risk of cervical cancer is lower for women who stop screening after a negative DNA test for oncogenic HPV.

In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.

With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing

A new genome sequence study suggests sequence conservation is more common in HPV16 isolates from individuals with cancer or pre-cancerous conditions.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.